Page last updated: 2024-11-05

pempidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pempidine is a quaternary ammonium compound that acts as a potent ganglion blocker. It was first synthesized in 1952 and was initially studied for its potential use in treating hypertension. Pempidine's effects on the autonomic nervous system make it useful in research studies investigating the role of the autonomic nervous system in various physiological processes. However, due to its significant side effects, including hypotension and dry mouth, it is no longer used clinically. Pempidine is still studied in research settings to understand the mechanisms of autonomic nervous system regulation and to develop new drugs for treating autonomic disorders.'

Pempidine: A nicotinic antagonist most commonly used as an experimental tool. It has been used as a ganglionic blocker in the treatment of hypertension but has largely been supplanted for that purpose by more specific drugs. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6603
CHEMBL ID1617409
CHEBI ID94718
SCHEMBL ID217663
MeSH IDM0016114

Synonyms (59)

Synonym
79-55-0
piperidine, 1,2,2,6,6-pentamethyl-
pempidine
NCGC00178703-01
NCGC00178703-02
pempidinum [inn-latin]
einecs 201-211-2
1,2,2,6,6-pentamethylpiperidine
m+b 4486
pempidine [inn:ban]
perolysen
pempidina [dcit]
tenormal
pyrilene
AB00053781
1,2,2,6,6-pentamethylpiperidine, 97%
inchi=1/c10h21n/c1-9(2)7-6-8-10(3,4)11(9)5/h6-8h2,1-5h3
xulixflcvxwhrf-uhfffaoysa-
AKOS005259835
nsc-758448
smr001550603
MLS004734620
pempidine, pempidine (1,2,2,6,6-pentamethylpiperidine)
CCG-205020
CHEMBL1617409
n5i18ji9d6 ,
unii-n5i18ji9d6
nsc 758448
pempidinum
pempidina
FT-0631351
S5725
SCHEMBL217663
pempidine [mi]
pempidine [who-dd]
pempidine [inn]
CS-4858
1,2,2,6,6-pentamethyl-piperidine
n-methyl-2,2,6,6-tetramethylpiperidine
1,2,2,6,6-penta-methylpiperidine
DTXSID7046962
m&b 4486
J-660028
1,2,2,6,6-pentamethylpiperidin
HY-B1382
AB00053781_08
mfcd00006493
1,2,2,6,6-pentamethylpiperidine, purum, >=99.0% (gc)
CHEBI:94718
D78083
SBI-0050913.P003
BBL102663
A857505
STL556467
DS-15962
Q1438667
BRD-K71075093-001-01-7
HMS3886G20
SY106910

Research Excerpts

Effects

ExcerptReferenceRelevance
"Thus pempidine has a stimulant action on the spinal and supraspinal centres."( Central vasomotor effects of a new ganglion-blocking agent--1: 2: 2: 6: 6-pentamethyl piperidine (pempidine).
BHARGAVA, KP; DHAWAN, KN, 1960
)
0.91
"Thus pempidine has a stimulant action on the spinal and supraspinal centres."( Central vasomotor effects of a new ganglion-blocking agent--1: 2: 2: 6: 6-pentamethyl piperidine (pempidine).
BHARGAVA, KP; DHAWAN, KN, 1960
)
0.91

Actions

ExcerptReferenceRelevance
"Pempidine was found to increase the ED50 of nicotine (0.73 mg/kg) for depression of spontaneous activity in a dose-related manner."( Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine.
Martin, BR; Martin, TJ; May, EL; Suchocki, J, 1990
)
1.22

Bioavailability

ExcerptReferenceRelevance
" Pempidine is well absorbed from the gastro-intestinal tract as judged by (a) the low ratio (6."( Pharmacological properties of pempidine (1:2:2:6:6-pentamethylpiperidine), a new ganglion-blocking compound.
CORNE, SJ; EDGE, ND, 1958
)
1.44
" All were well absorbed when administered orally."( The pharmacological actions of pempidine and its ethyl homologue.
DUNLOP, D; FARRINGTON, JA; SPINKS, A; YOUNG, EH, 1958
)
0.52

Dosage Studied

ExcerptRelevanceReference
" The alteration of nicotine's dose-response curves for depression of spontaneous activity and antinociception was determined in the presence of increasing concentrations of pempidine."( Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine.
Martin, BR; Martin, TJ; May, EL; Suchocki, J, 1990
)
0.69
" Supersensitivity was observed, after daily oral dosing with hyoscine, in the increased salivation of mice in response to pilocarpine injected at least 66 h after withdrawing hyoscine."( Supersensitivity of salivation in response to pilocarpine after withdrawal of chronically administered hyoscine in the mouse.
Parkes, MW; Parks, JC, 1972
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (167)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990152 (91.02)18.7374
1990's10 (5.99)18.2507
2000's3 (1.80)29.6817
2010's2 (1.20)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.87 (24.57)
Research Supply Index5.23 (2.92)
Research Growth Index3.91 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.09%)5.53%
Reviews4 (2.19%)6.00%
Case Studies2 (1.09%)4.05%
Observational0 (0.00%)0.25%
Other175 (95.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]